杨巍维：丙酮酸激酶M2亚型在EGFR促进的癌症发生中的作用及机制
肿瘤细胞，即使在氧气充足的情况下，仍倾向于利用糖酵解的方式代谢葡萄糖，在摄取大量葡萄糖的同时排出大量的乳酸，这个现象被称为“Warburg效应”。可以肯定的是，糖酵解赋予了肿瘤细胞独特的生长优势，但这种优势形成的内在机制仍不清楚。
有研究认为，肿瘤细胞利用大部分葡萄糖代谢中间产物合成生物大分子（氨基酸，核酸以及磷脂），从而支持肿瘤细胞的快速生长。我们的研究则发现糖酵解以另外一种全新机制赋予肿瘤细胞生长优势。
本报告将以丙酮酸激酶M2（PKM2）为切入点，围绕细胞核内PKM2的功能，着重探讨了PKM2的“非代谢”功能在癌症发生、发展中的作用及机制。
蛋白激酶的结构 - Susan Taylor
In this lecture, I have given an overview of protein kinase structure and function using cyclic AMP dependent kinase (PKA) as a prototype for this enzyme superfamily. I have demonstrated what we have learned from the overall structural kinome which allows us to compare many protein kinases and also to appreciate how the highly regulated eukaryotic protein kinase has evolved. By comparing many protein kinase structures, we are beginning to elucidate general rules of architecture. In addition, I have attempted to illustrate how PKA is regulated by cAMP and how it is localized to specific macromolecular complexes through scaffold proteins.
蛋白激酶的调控与定位- Susan Taylor
In this lecture, I have given an overview of protein kinase structure and function using cyclic AMP dependent kinase (PKA) as a prototype for this enzyme superfamily. I have demonstrated what we have learned from the overall structural kinome which allows us to compare many protein kinases and also to appreciate how the highly regulated eukaryotic protein kinase has evolved. By comparing many protein kinase structures, we are beginning to elucidate general rules of architecture. In addition, I have attempted to illustrate how PKA is regulated by cAMP and how it is localized to specific macromolecular complexes through scaffold proteins.
耽美玉：激酶抑制疗效监控标志物研究
介绍了敏感标志物在加快药物研发进程中发挥的重要作用，介绍了肿瘤药物治疗的困境：临床响应率依然有限、获得耐药性容易发生、原发性耐药广泛存在。介绍了需要关注的科学问题：理性靶点群VS联合用药策略、肿瘤细胞自身VS肿瘤免疫微环境。介绍了4个同步策略。介绍了高选择性C-Met抑制剂SCC244-疗效监控标志物的研究。
俞强：肿瘤细胞酪氨酸激酶信号通路的异质性和个性化治疗
从肿瘤是一个异质性的疾病讲起，介绍了细胞生长信号通路与肿瘤的关系，提到了让人蛋白酪氨酸激酶组及主要药物靶点的RTk。提到了肿瘤细胞蛋白酪氨酸磷酸化的异质性，肠癌细胞株ＲＴＫ磷酸化的异质性以及指纹图谱。也介绍了个性化的肿瘤诊断和药物治疗方法。